Trovagene to Offer Clinical Data on Co.'s Urine-Based Liquid Biopsy Platform at Two Upcoming Conferences

Trovagene, Inc.

, a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer MonitoringSM platform will be presented at the 2015 Cancer Markers and Liquid Biopsies conference in San Diego, CA on June 11-12, and at the AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy in Salt Lake City, UT on June 13-16. A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease. "We continue to advance our clinical programs and present data to the medical community demonstrating the advantages of using our urine-based molecular diagnostics in the management of various cancer types," stated Mark Erlander, Ph.D., chief scientific officer of Trovagene. "The data sets to be presented at these conferences support the clinical utility of our non-invasive cancer monitoring tests in both lung and colorectal cancers, and their ability to empower oncologists to detect and quantitatively track driver mutations to improve treatment decisions." 2015 Cancer Markers and Liquid Biopsies June 11 2015, 11:25 a.m. PDT Oral Presentation Early Pharmacodynamics Using Urinary ctDNA as a Putative Biomarker of Drug Response Presenter: Mark Erlander, Ph.D., Trovagene, Inc. Highlights: High frequency testing of circulating tumor (ct)DNA mutations in patients receiving molecularly targeted therapies can be used to determine early changes in mutation load brought about by treatment administration, in addition to tumor dynamics when used to monitor treatment response longitudinally June 12 2015, 10:45 a.m. PDT Oral Presentation Monitoring Urinary Circulating Tumor DNA (ctDNA) KRAS for Treatment Response in Patients with Metastatic Colorectal Cancer (mCRC) Collaborator: Afsaneh Barzi, M.D., USC Norris Comprehensive Cancer Center Highlights: Potential to guide treatment decisions in metastatic colorectal cancer (mCRC) patients based on ctDNA KRAS mutation dynamics AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy June 15, 2015, 12:30 – 3:00 p.m. CDT Poster Session Quantitative Monitoring of EGFR Mutations in Urinary Circulating Tumor DNA Enables Non-Invasive Pharmacodynamic Assessment of Anti-EGFR Drug Response Single Cell and Circulating Free Nucleic Acid Sequencing Session, Abstract: # 29 Collaborator: Hatim Husain, M.D., UCSD Moores Cancer Center Highlights: Urine-based EGFR ctDNA assay has been shown to outperform tissue biopsy for the detection of EGFR T790M mutations in metastatic lung cancer patients Non-invasive liquid biopsy enables detection of emerging T790M mutations with greater sensitivity than tissue biopsy, and months before detection of cancer progression with imaging Tracking ctDNA in urine enables determination of response to next generation EGFR T790M inhibitors within days of initial treatment